{"DataElement":{"publicId":"6922131","version":"1","preferredName":"Transplant Conditioning Without HPV-16 E7 TCR Expressing T-cells Begin Yes No Indicator","preferredDefinition":"Indication whether the patient began the conditioning chemotherapy regimen without receiving HPV-16 E7 TCR expressing t-cells.","longName":"CND_WO_TCELL_BGN_IND","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"6922128","version":"1","preferredName":"Transplant Conditioning Without HPV-16 E7 TCR Expressing T-cells Begin","preferredDefinition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection)._Used to indicate the absence or lack of something or someone._A preparation of allogeneic, genetically engineered T-lymphocytes transduced with a retroviral vector MSGV1 that encodes a T-cell receptor (TCR) targeting a specific epitope of the human papillomavirus (HPV) type 16 oncoprotein E7 (HPV-16 E7 TCR), with potential antineoplastic activity. The TCR especially recognizes and binds with high affinity to the HPV 16 E7 11-19 epitope. Upon administration, HPV-16 E7 expressing T-cells target and bind to tumor cells expressing the HPV-16 E7 antigen leading to selective cytotoxicity in HLA-A2-positive, HPV-16 E7-expressing tumor cells. HPV16 E7, a tumor-associated antigen (TAA), overexpressed in a variety of tumor cell types while not expressed in normal, healthy cells, plays a key role in tumor cell proliferation. E7 11-19 is a naturally processed epitope of HPV-16 E7 that binds specifically to human leukocyte antigen (HLA)-A*02:01 and that has been isolated from the surface of HPV-16 positive, HLA-A*02:01-positive tumor cells._Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","longName":"2594982v1.0:6922126v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2594982","version":"1","preferredName":"Transplant Conditioning","preferredDefinition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy,\r\nto a transplant.","longName":"C64468","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplant Conditioning","conceptCode":"C64468","definition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"294AEA36-A991-5261-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-12","modifiedBy":"ONEDATA","dateModified":"2007-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6922126","version":"1","preferredName":"Without HPV-16 E7 TCR Expressing T-cells Begin","preferredDefinition":"Used to indicate the absence or lack of something or someone.:A preparation of allogeneic, genetically engineered T-lymphocytes transduced with a retroviral vector MSGV1 that encodes a T-cell receptor (TCR) targeting a specific epitope of the human papillomavirus (HPV) type 16 oncoprotein E7 (HPV-16 E7 TCR), with potential antineoplastic activity. The TCR especially recognizes and binds with high affinity to the HPV 16 E7 11-19 epitope. Upon administration, HPV-16 E7 expressing T-cells target and bind to tumor cells expressing the HPV-16 E7 antigen leading to selective cytotoxicity in HLA-A2-positive, HPV-16 E7-expressing tumor cells. HPV16 E7, a tumor-associated antigen (TAA), overexpressed in a variety of tumor cell types while not expressed in normal, healthy cells, plays a key role in tumor cell proliferation. E7 11-19 is a naturally processed epitope of HPV-16 E7 that binds specifically to human leukocyte antigen (HLA)-A*02:01 and that has been isolated from the surface of HPV-16 positive, HLA-A*02:01-positive tumor cells.:Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","longName":"C25718:C128485:C25431","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"HPV-16 E7 TCR Expressing T-cells","conceptCode":"C128485","definition":"A preparation of allogeneic, genetically engineered T-lymphocytes transduced with a retroviral vector MSGV1 that encodes a T-cell receptor (TCR) targeting a specific epitope of the human papillomavirus (HPV) type 16 oncoprotein E7 (HPV-16 E7 TCR), with potential antineoplastic activity. The TCR especially recognizes and binds with high affinity to the HPV 16 E7 11-19 epitope. Upon administration, HPV-16 E7 expressing T-cells target and bind to tumor cells expressing the HPV-16 E7 antigen leading to selective cytotoxicity in HLA-A2-positive, HPV-16 E7-expressing tumor cells. HPV16 E7, a tumor-associated antigen (TAA), overexpressed in a variety of tumor cell types while not expressed in normal, healthy cells, plays a key role in tumor cell proliferation. E7 11-19 is a naturally processed epitope of HPV-16 E7 that binds specifically to human leukocyte antigen (HLA)-A*02:01 and that has been isolated from the surface of HPV-16 positive, HLA-A*02:01-positive tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Begin","conceptCode":"C25431","definition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9239D4CB-1124-3113-E053-F662850AE3D7","latestVersionIndicator":"Yes","beginDate":"2019-09-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-09-10","modifiedBy":"ONEDATA","dateModified":"2019-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9239D4CB-1135-3113-E053-F662850AE3D7","latestVersionIndicator":"Yes","beginDate":"2019-09-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-09-10","modifiedBy":"HARTLEYG","dateModified":"2019-09-19","changeDescription":"Curated to support Protocol P19C0130","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient starts the conditioni","type":"Preferred Question Text","description":"Patient starts the conditioning regimen chemotherapy but does not receive the E7 TCR T Cells","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"92380E2F-2B48-4CD6-E053-F662850A5FE6","latestVersionIndicator":"Yes","beginDate":"2019-09-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-09-10","modifiedBy":"COOPERM","dateModified":"2020-04-21","changeDescription":"Curated to support Protocol P19C0130","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}